1039 ET - Gilead Sciences are weaker following news the Health and Human Services Department is considering cutting funding for HIV prevention, but analysts believe that threat poses only moderate risk. Potential cuts to CDC funding would not limit access to pre-exposure prophylaxis, a preventative treatment for HIV patients, because the organization only works on research, not providing the drugs, JPMorgan analysts say. The Centers for Disease Control and Prevention, which is part of HHS, spent about $1.3 billion in HIV funding as of 2023, BMO analyst Evan David Seigerman says, the removal of which "should only represent a modest headwind" to Gilead. Gilead is off 3.7%. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:39 ET (14:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.